Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.360
-0.080 (-2.33%)
At close: May 30, 2025, 4:00 PM
3.410
+0.050 (1.49%)
After-hours: May 30, 2025, 5:43 PM EDT
Arbutus Biopharma Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Arbutus Biopharma stock ranges from a low of $5.00 to a high of $7.00. The average analyst price target of $5.50 forecasts a 63.69% increase in the stock price over the next year.
Price Target: $5.50 (+63.69%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for Arbutus Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +48.81% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +48.81% | Jan 21, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +48.81% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +48.81% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +48.81% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
7.07M
from 6.17M
Increased by 14.57%
Revenue Next Year
8.19M
from 7.07M
Increased by 15.84%
EPS This Year
-0.24
from -0.38
EPS Next Year
-0.21
from -0.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.8M | 8.4M | 9.3M | ||
| Avg | 7.1M | 8.2M | 9.0M | ||
| Low | 6.2M | 7.9M | 8.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 42.9% | 19.2% | 13.2% | ||
| Avg | 14.6% | 15.8% | 10.0% | ||
| Low | 0.0% | 11.3% | 5.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.17 | -0.11 | -0.05 | ||
| Avg | -0.24 | -0.21 | -0.05 | ||
| Low | -0.31 | -0.28 | -0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.